Información del artículo
Resumen
La homocisteína es un aminoácido no esencial que ha resultado ser un nuevo factor de riesgo cardiovascular independiente y un posible marcador biológico de las complicaciones ocurridas durante la gestación. Su tratamiento es fácil e inocuo, la prevalencia parece ser alta y su determinación mediante nuevas técnicas automatizadas hará posible que se realice en cualquier laboratorio. Esto nos hace pensar en la homocisteína como un posible factor de cribado poblacional, especialmente en aquellos pacientes con un mayor riesgo cardiovascular y en mujeres gestantes con antecedentes de embarazo complicado. Pero, por ahora, es una prueba que sólo se realiza en la investigación clínica
Palabras clave:
Homocisteína
Factor de riesgo
Gestación
Enfermedad cardiovascular
Ácido fólico
Abstract
Homocysteine is a non-essential amino acid that has been identified as a new independent cardiovascular risk factor and a possible biological marker of complications during pregnancy. Treatment is easy and effective. Homocysteine seems to be highly prevalent and its determination through new automatized techniques will mean that it can be identified in all laboratories. Therefore, this amino acid may become a factor in population streeming, especially in patients at high risk for cardiovascular disease and in gestating women with a history of complications in pregnancy. However, at present, these possibilities are still at the stage of clinical research
Keywords:
Homocysteine
Risk factor
Gestation
Cardiovascular disease
Folic acid
El Texto completo está disponible en PDF
Bibliografía
[1.]
N.A.J. Carson, D.W. Neill.
Metabolic abnormalities detected in a survey of mentally backward individuals in Nothern Ireland.
Arch Dis Child, 37 (1962), pp. 505-513
[2.]
S.H. Mudd, J.D. Finkelstein, F. Irreverre.
Homocystinuria: an enzimatic defect.
Science, 143 (1964), pp. 1443-1445
[3.]
K.S. McCully.
Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis.
Am J Pathol, 56 (1969), pp. 111-128
[4.]
S.H. Mudd, B.W. Unlendorf, J.M. Freeman, J.D. Finkelstein, V.E. Shid.
Homocystinuria asociated with decreased MTHFR activity.
Biochem Biophys Res Commun, 46 (1972), pp. 905-912
[5.]
M.J. Stampfer, M.R. Malinow, W.C. Willet, L.M. Newcomer, B. Upson, D. Ullmann, et al.
A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians.
Jama, 268 (1992), pp. 877-881
[6.]
I.J. Perry, H. Refsum, R.W. Morris, S.B. Ebrahim, P.M. Ueland, A.G. Shaper, et al.
Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.
Lancet, 346 (1995), pp. 1395-1398
[7.]
O. Nygard, J.E. Nordrehaug, H. Refsum, P.M. Ueland, M. Farstad, S.E. Vollset.
Plasma homocysteine levels and mortality in patiens with coronary artery disease.
N Engl J Med, 337 (1997), pp. 230-236
[8.]
I.M. Graham, L.E. Daly, H.M. Refsum, K. Robinson, L.E. Brattstrom, P.M. Ueland, et al.
Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project.
Jama, 277 (1997), pp. 1775-1781
[9.]
R.P. Steegers-Theunissen, G.H. Boers, F.J. Trijbels, J.D. Finkelstein, H.J. Blom, C.M. Thomas, et al.
Maternal hyperhomocysteinemia: A risk factor for neural tube defects. Metabolism.
Clin and Exp, 43 (1994), pp. 1475-1480
[10.]
F.J. Vollset.
Non-syndromic orofacial clefts: association with maternal hyper-homocisteinemia [resumen].
Nljmav, 52 (1998), pp. S34
[11.]
E. Joosten, E. Lesaffre, R. Riezler, V. Ghekiere, L. Dereymaeker, W. Pelemans, et al.
Is metabolic evidence for vitamin B12 and folate deficiency more frequent in elderly patiens with Alzheimer's disease?.
J Gerontol, 52A (1997), pp. 76-79
[12.]
E.K. Hoogeveen.
Hyperhomocyteinemia is a predictor of overall mortality: the Horn Study [resumen].
Nljmav, 52 (1998), pp. S9
[13.]
G.N. Welch, L. Loscalzo.
Homocysteine and atherothrombosis.
N Engl J Med, 338 (1998), pp. 1042-1050
[15.]
A. Córdoba, F. Blanco, F. González.
Bases moleculares de la hiperhomocisteinemia.
Química Clínica, 17 (1998), pp. 5-18
[16.]
P.M. Ueland, H. Refsum, S.P. Stabler, M.R. Malinow, A. Anderson, R.H. Allen.
Total Homocysteine in plasma or serum: methods and clinical applications.
Clin Chem, 39 (1993), pp. 1764-1779
[17.]
C. Bolander-Gouaille.
What is homocysteine?.
Determination of homocysteine. Why, when and how, pp. 11-13
[18.]
D.W. Jacobsen, V.J. Gatautis, R. Green, K. Robinson, S.R. Savon, M. Secic, et al.
Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects.
Clin Chem, 40 (1994), pp. 873-881
[19.]
M.C. Walker, G.N. Smith, S.L. Perkins, E.J. Keeley, P.R. Garner.
Changes in homocysteine levels during normal pregnancy.
Am J Obstet Gynecol, 180 (1999), pp. 660-664
[20.]
M.R. Malinow, A. Rajkovic, P.B. Duell, D.L. Hess, B.M. Upson.
The relationship between maternal and neonatal umbilical cord plasma homocysteine suggests a potential role for maternal homocysteine in fetal metabolism.
Obstet Gynecol, 178 (1998), pp. 228-233
[21.]
S.S. Kang, P.W. Wong, M.R. Malinow.
Hyperhomocysteinemia as a risk factor for occlusive vascular disease.
Ann Rev Nutr, 12 (1992), pp. 279-298
[22.]
T.Y. Khong, W.M. Hague.
The placente in maternal hyperhomocysteinemia.
Br J Obstet Gynecol, 106 (1999), pp. 273-278
[23.]
A.G. Bostom, P.F. Jacques, M.R. Nadeau, R.R. Williams, R.C. Ellison, J. Selhub.
Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study.
Atherosclerosis, 116 (1995), pp. 147-151
[24.]
J.H. Stein, P.E. Mcbride.
Hyperhomocysteinemia and atherosclerotic vascular disease.
Arch Intern Med, 158 (1998), pp. 1301-1306
[25.]
C. Bolander-Gouaille.
Why do homocysteine levels increase?.
Determination of homocysteine. Why, when and how, pp. 25-35
[26.]
A.R. Folsom, F.J. Nieto, P.G. McGovern, M.Y. Tsai, M.R. Malinow, J.H. Eckfeldt, et al.
Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. ARIC Study.
Circulation, 98 (1998), pp. 204-210
[27.]
S.M. Carlsen, I. Folling, V. Grill, K.S. Bjerve, J. Schneede, H. Refsum.
Metformin increases total serum homocisteyne levels in non-diabetic male patients with coronary heart disease.
Scand J Clin Lab Invest, 57 (1997), pp. 521-527
[28.]
MRC Vitamin Study Research Group.
Prevention of neural tube defects: Results of the Medical Research Council Vitamin study.
Lancet, 338 (1991), pp. 131-136
[29.]
R.P.M. Steegers-Theunissen, G.H.J. Boers, F.J.M. Trijbels.
Maternal hyper-homocysteinemia: a risk factor for neural tube defects?.
Metabolism, 43 (1994), pp. 1475-1480
[30.]
J.L. Mills, J.M. McPartlin, P.N. Kirke, Y.J. Lee, M.R. Conley, D.G. Weir.
Homocisteine metabolism in pregnancies complicated by neural tube defects.
Lancet, 345 (1995), pp. 149-151
[31.]
R.P.M. Steegers-Theunissen, G.H.J. Boers, H.J. Blom, J.G. Nijhuis, C.M. Thomas, G.F. Borm, et al.
Neural tube defects and elevated homocysteine levels in amniotic fluid.
Am J Obstet Gynecol, 172 (1995), pp. 1436-1441
[32.]
T.H. Rosenquist, S.A. Ratashak, J. Selhub.
Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid.
Proc Natl Acad Sci USA, 93 (1996), pp. 15227-15232
[33.]
W.Y. Wong, T.K. Eskes, A.M. Kuijpers-Jagtman, P.H. Spauwen, E.A. Steegers, C.M. Thomas, et al.
Nonsyndromic orofacial clefts: association with maternal hyperhomocysteinemia.
Teratology, 60 (1999), pp. 253-257
[34.]
S.E. Vollset, H. Refsum, L.M. Irgens, B.M. Emblem, A. Tverdal, H.K. Gjessing.
Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study.
Am J Nutr, 71 (2000), pp. 962-968
[35.]
R.P.M. Steegers-Theunissen, G.H.J. Boers, H.J. Blom, F.J.M. Trijbels, T.K.A.B. Eskers.
Hyperhomocisteinemia and recurrent spontaneous abortion or abruptio placentae.
Lancet, 339 (1992), pp. 112-113
[36.]
I. Quere, H. Bellet, M. Hoffet, C. Janbon, P. Mares, J.C. Gris.
A woman with five consecutive fetal deaths: case report and retrospective analysis of hyperhomocysteinemia prevalence en 100 consecutive women with recurrent miscarriages.
Fertil Steril, 69 (1998), pp. 152-154
[37.]
W.L.D.M. Nelen, H.J. Blom, E.A.P. Steegers, M. Den Heijer, C.M.G. Thomas, T.K.A.B. Eskers.
Homocysteine and folate levels as risk factors for recurrent early pregnancy loss.
Obstet Gynecol, 95 (2000), pp. 519-524
[38.]
R.W. Powers, R.W. Evans, A.K. Majors, J.I. Ojimba.
Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation.
Am J Obstet Gynecol, 179 (1998), pp. 1605-1611
[39.]
H. Laivuori, U. Turpeinen, L. Vinikka, O. Ylikorkala.
Plasma homocysteine levels elevated and inversely related to insulin sensitivy in preeclampsia.
Obstet Gynecol, 93 (1999), pp. 489-493
[40.]
A. Rajkovic, K. Mahomed, M.R. Malinow, T.K. Sorenson.
Plasma homocysteine concentrations in eclamptic and preeclamptic african women postpartum.
Obstet Gynecol, 94 (1999), pp. 355-360
[41.]
T.K. Sorenson, M.R. Malinow, M.A. Willians, I.B. King, D.A. Luthy.
Elevated second trimester serum homocysteine levels and subsequent risk of preeclampsia.
Gynecol Obstet Invest, 48 (1999), pp. 98-103
[42.]
A.F. Fleming, J.D. Martin, J.R. Hahnel, A.J. Westlake.
Effects of iron and folic acid antenatal supplements on maternal haematology and fetal wellbeing.
Med J Aust, 2 (1974), pp. 4294
[43.]
J. Fletcher, A. Gurr, F.R. Fellingham, T.A.J. Prankerd, H.A. Brant, D.N. Menzies.
The value of folic acid supplements in pregnancy.
J Obstet Gynecol Br Commw, 78 (1971), pp. 781-785
[44.]
P.F.H. Giles, A.G. Harcourt, M.G. Whiteside.
The effect of prescribing acid during pregnancy on birth-weight and duration of pregnancy.
Med J Aust, 2 (1971), pp. 17-21
[45.]
N. Baumslag, T. Edelstein, J. Metz.
Reduction of incidence of prematurity by folic acid supplementation in pregnancy.
Br Med J, 1 (1970), pp. 16-17
[46.]
L. Iyengar, K. Rajalakshmi.
Effect of folic acid supplement on birth weights of infants.
Am J Obstet Gynecol, 122 (1975), pp. 332-336
[47.]
J. Rolschau, J. Date, K. Kristoffersen.
Folic acid supplement and intrauterine growth.
Acta Obstet Gynecol Scand, 58 (1979), pp. 343-344
[48.]
I. Blot, E. Papiernik, J.P. Kaltwasser, E. Werner, G. Tchernia.
Influence of routine administration of folic acid and iron during pregnancy.
Gynecol Obstet Invest, 12 (1981), pp. 294-304
[49.]
A.E. Czeizel, I. Dudas, J. Metneki.
Pregnancy outcomes in a randomised controlled trial of periconceptional multivitaminin supplementation.
Arch Gynecol Obstet, 255 (1994), pp. 131-139
[50.]
M.R. Malinow, A.G. Bostom, R.M. Krauss.
Homocyst(e)ine, diet and cardiovascular diseases.
Circulation, 99 (1999), pp. 178-182
[51.]
M.R. Malinow, P.B. Duell, D.L. Hess, P.H. Anderson, W.D. Kruger, B.E. Phillipson, et al.
Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.
N Engl J Med, 338 (1998), pp. 1009-1015
[52.]
P.F. Jacques, J. Selhub, A.G. Bostom, P.W. Wilson, I.H. Rosenberg.
The effect of folic acid fortification on plasma folate and total homocysteine concentrations.
N Engl J Med, 340 (1999), pp. 1449-1454
[53.]
E.B. Rimm, W.C. Willet, F.B. Hu, L. Sampson, G.A. Colditz, J.E. Manson, et al.
Folate and Vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women.
Jama, 279 (1998), pp. 359-364
[54.]
H. McNulty, G.J. Cuskelly, M. Ward.
Response of red blood cell folate to intervencition: implications for folate recomendations for the prevention of neural tube defects.
J Clin Nutr, 71 (2000), pp. S1308-S1311
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia